Department of Neurology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901-1962, USA.
Epilepsia. 2011 Oct;52(10):e153-5. doi: 10.1111/j.1528-1167.2011.03212.x. Epub 2011 Jul 29.
Dose-dependent PR interval prolongation has been reported in preclinical studies of lacosamide (LCM), a recently U.S. Food and Drug Administration (FDA)-approved antiepileptic drug (AED). Here we report a case of second-degree atrioventricular block (AV) block caused by the addition of LCM to other AEDs known to prolong the PR interval, resulting in hypotension and bradycardia, with consequent seizure exacerbation. The patient recovered completely after withdrawal of LCM. This case demonstrates the need for caution and interval cardiac testing when adding LCM to other AEDs known to prolong the PR interval.
在拉科酰胺（LCM）的临床前研究中，有报道称其具有剂量依赖性 PR 间期延长作用，LCM 是一种最近获得美国食品和药物管理局（FDA）批准的抗癫痫药物（AED）。在这里，我们报告了一例由 LCM 与已知可延长 PR 间期的其他 AED 联合使用引起的二度房室传导阻滞（AV）阻滞，导致低血压和心动过缓，进而导致癫痫发作恶化。停用 LCM 后，患者完全恢复。该病例表明，在将 LCM 添加到已知可延长 PR 间期的其他 AED 时，需要谨慎并进行间隔性心脏检查。
